Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Masato Uji (Osaka, Japan), Masato Uji, Yuko Kureya, Kazuhiro Yamada, Tetsuya Watanabe, Kazuhisa Konishi, Kazuhisa Asai, Tatsuo Nakamura, Kazuto Hirata. Effect of intratracheal administration of adipose-derived stromal cells on bleomycin-induced lung injury in a rat model. Eur Respir J 2015; 46: Suppl. 59, 943

Member's Comments

No comment yet.

Related content which might interest you: Comparative effects of inhaled and intravenous mesenchymal stem cells in bleomycin-induced pulmonary fibrosis in rabbits Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Abnormal proliferation and differentiation of c-kit+ lung stem cells in pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Chronic intermittent hypoxia exacerbates lung fibrosis in bleomycin-induced lung injury mouse model Source: International Congress 2018 – Sleep-disordered breathing: cardiovascular consequences, epidemiology, phenotypes and comorbidities Year: 2018 Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 KCa3.1 channel inhibition prevents fibrotic responses in a human lung explant model Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 FGF-9 overexpression prevents pleural fibrosis induced by intra-pleural adenovirus injection in mice Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Role of Bcl-xL in hepatocyte growth factor elicited epithelial protection in idiopathic lung fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis Year: 2013 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016